TD Cowen analyst Ritu Baral downgraded Avidity Biosciences (RNA) to Hold from Buy with a price target of $74, down from $78, after the company entered into a merger agreement with Novartis (NVS) for $72 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Hold Rating Issued Amid Avidity Biosciences Acquisition and Strategic Restructuring
- Warner Bros. Discovery upgraded, F5 downgraded: Wall Street’s top analyst calls
- Avidity Biosciences downgraded to Neutral from Buy at Citi
- Avidity Biosciences downgraded to Neutral from Buy at Chardan
- Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital